Janssen Biotech, Inc. Sustainability Profile
Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, it has rapidly established itself in the biotechnology industry, focusing on innovative treatments in areas such as immunology, oncology, and infectious diseases. With a commitment to advancing healthcare, Janssen Biotech is renowned for its core products, including biologics and targeted therapies that address complex medical conditions. The company’s unique approach to drug development and its robust pipeline have positioned it as a key player in the global market. Notable achievements include the successful launch of groundbreaking therapies that have transformed patient care, solidifying Janssen Biotech's reputation for excellence and innovation in the biopharmaceutical landscape.
DitchCarbon Score
How does Janssen Biotech, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Janssen Biotech, Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Janssen Biotech, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, which influences its climate commitments and emissions reporting. As part of its corporate family, Janssen Biotech inherits climate initiatives and targets from Johnson & Johnson. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing carbon emissions and promoting sustainability. However, specific reduction targets or achievements for Janssen Biotech are not detailed in the available data. While no absolute emissions figures are provided, the commitment to sustainability and climate action is evident through the initiatives cascaded from Johnson & Johnson. The company is aligned with industry standards for climate action, focusing on reducing its carbon footprint and contributing to broader environmental goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Janssen Biotech, Inc.'s Industry?
How Carbon Intensive is Janssen Biotech, Inc.'s Location?
Janssen Biotech, Inc.'s Scope 3 Categories Breakdown
Janssen Biotech, Inc.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Janssen Biotech, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Janssen Biotech, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
